Investment Rating - The report maintains a "Buy" rating for JD Health [3][8]. Core Insights - JD Health achieved a revenue of 73.44 billion RMB in 2025, representing a year-on-year growth of 26.3%. The company's product revenue grew by 24.8% to 60.88 billion RMB, while service revenue increased by 34.1% to 12.56 billion RMB [8]. - The gross margin improved by 1.9 percentage points to 24.8%, driven by a higher proportion of high-margin service revenue and optimization of product structure [8]. - The annual profit reached 5.37 billion RMB, a 29.1% increase year-on-year, with Non-IFRS net profit hitting 6.53 billion RMB, up 36.3%, marking a historical high [8]. - The number of active users increased to 218 million, a net addition of 34.1 million from the previous year [8]. - The company launched over 100 new drugs in 2025, significantly up from more than 30 in 2024, reinforcing its position as a leader in new drug launches [8]. - The service revenue growth was fueled by an increase in the number of platform advertisers, leading to a rise in digital marketing service fees [8]. - JD Health's AI-enabled services and expansion of offline stores contributed to a comprehensive health service model, integrating online and offline operations [8]. - The report forecasts revenue growth for 2026-2028 at 85.57 billion RMB, 97.99 billion RMB, and 108.05 billion RMB, respectively, with adjusted net profits of 6.6 billion RMB, 7.6 billion RMB, and 8.4 billion RMB [8]. Financial Metrics Summary - Revenue for 2025 is projected at 73.44 billion RMB, with a growth rate of 26.3% [2]. - Adjusted net profit for 2025 is estimated at 6.53 billion RMB, reflecting a growth rate of 36% [2]. - The earnings per share (EPS) based on adjusted net profit is expected to be 2.03 RMB for 2025, with a price-to-earnings (P/E) ratio of 21 [2]. - The price-to-book (P/B) ratio is projected to be 2.3 for 2025 [2].

Core Insights - JD Health is expanding its partnerships with over 20 multinational pharmaceutical companies, focusing on a comprehensive health ecosystem rather than just selling medications [1] - During the 11.11 shopping festival, JD Health reported that over 7,000 brands saw their transaction volumes double year-on-year across its pharmaceutical, nutritional, and medical device sectors [1] - The company has established a robust supply chain that supports the rapid launch of innovative drugs, exemplified by the swift introduction of a new drug within just 7 days [4] Group 1: Supply Chain and Innovation - JD Health has become the preferred online channel for multinational pharmaceutical companies to launch innovative drugs in China, with over 30 new drugs launched in the first half of the year [4] - The company has built a nationwide supply chain network with 33 warehouses, including 22 specialized cold chain warehouses, ensuring temperature-sensitive products are delivered safely [4] - The "JD Buy Medicine Fast Delivery" system can deliver medications in as little as 9 minutes, showcasing the efficiency of its logistics capabilities [4] Group 2: Market Expansion and Consumer Trends - The 11.11 festival saw over 2,500 pharmaceutical brands achieving transaction volumes that doubled year-on-year, highlighting JD Health's role in enhancing the accessibility of innovative drugs [5] - The nutritional supplement category has shown significant growth, with nearly 100 subcategories experiencing over 100% year-on-year growth during the same period [8] - Products like traditional health supplements saw transaction volumes increase by over 200%, indicating a shift towards more health-conscious consumer behavior [8] Group 3: Integrated Health Services - JD Health is transitioning from a transactional model to a comprehensive health service model, providing a full-service ecosystem that includes prevention, diagnosis, treatment, and long-term health management [7] - The integration of online consultations, rapid testing, and home healthcare services has created a seamless healthcare experience for users [8] - The company has expanded its health service offerings, with home healthcare orders increasing by 239% during the 11.11 festival [8] Group 4: AI and Digital Transformation - AI is being leveraged to enhance health service experiences, with JD Health integrating AI into clinical decision-making and health management [11] - The introduction of AI-driven health management tools has led to significant growth in medical device sales, with over 2,000 brands seeing transaction volumes double year-on-year [11] - AI personnel, including AI doctors and nutritionists, have significantly improved user engagement and satisfaction, with a 98% satisfaction rate reported [11] Group 5: Strategic Shift in Business Model - JD Health is evolving from merely being a sales platform to becoming a vital growth engine for global health brands, focusing on service depth and value co-creation [12] - The company is fostering a collaborative ecosystem with pharmaceutical companies, moving from channel partnerships to comprehensive ecosystem building [7]